Status:
COMPLETED
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Lead Sponsor:
Elena Gonzalez Brant, MD
Collaborating Sponsors:
University of Pittsburgh
Conditions:
Hidradenitis Suppurativa
Hidradenitis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas ...
Detailed Description
Hidradenitis suppurativa is a debilitating and mutilating disease and its pathogenesis is still poorly understood. It involves the development of recurrent, painful nodules in intertriginous areas tha...
Eligibility Criteria
Inclusion
- Patients with hidradenitis suppurativa Hurley stage I or II
Exclusion
- Current systemic immunosuppression, current use of biologic medication or use of these medications in the prior 3 months, patients with known retinal disease, hepatic disease (HCV, cirrhosis, aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of normal), psoriasis, porphyria cutanea tarda, platelets \< 50,000/ul, leukocytes \<4000/ul, or Hb\<8g/dl), pregnant patients or women trying to conceive
Key Trial Info
Start Date :
September 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03275870
Start Date
September 28 2017
End Date
June 30 2019
Last Update
April 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213